First, establish the trajectory of clinical and biomarker changes during the prodromal stage in LRRK2 NMCs and second, elucidate clinical outcomes and/or biomarkers that can identify the LRRK2 NMC subgroup at the highest risk of developing PD. Here, LRRK2 is linked to Parkinson disease.